Sin embargo, este mtodo conlleva riesgos , como reacciones alrgicas, dolor en el lugar de la inyeccin y complicaciones relacionadas con una administracin inadecuada
Nat Rev Immunol (2003) 3:13346
The mixed solution (10 mL) will provide a single 10 mL dose [see Dosage and Administration (2.3) and Description (11)]
Choi IS, Kook H, Han DK, Baek HJ, Jung ST, Lee JH et al (2007) Melanotic neuroectodermal tumor of infancy in the femur: a case report and review of the literature
Despite the prior unavailability of specific inhibitors targeting PRMT1 and the recent development of GSK3368715 as a highly potent inhibitor, the Phase 1 clinical trial employing GSK3368715 for PRMT1-targeted therapy was prematurely terminated due to its suboptimal clinical efficacy and extensive treatment-associated adverse effects (56)